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ABSTRACT
Objectives: The study has been designed to develop, test reliability, and construct validity of a novel versatile causality assessment tool (VCAT) method.
Methods: The study included 427 literature case reports of angiotensin-converting enzyme inhibitors with suspected adverse drug reactions from 
1990 to February 25, 2016. The causality of these cases was assessed independently by 3 raters in 3 phases of the study. Kappa (k) and intra-class 
correlation Intraclass Correlation Coefficient (ICC) were used to test reliability and validity of the VCAT method.
Results: Intra-rater reliability was high between Phase I and Phase III (k=0.84–0.93; % agreement: 92.3–96.3%). Inter-rater agreement was good in 
Phase I (k=0.87–0.89, % agreement: 93.7–94.1%, ICC: 0.975) and Phase III (k=0.85–0.89, % agreement: 93–94.4%, ICC: 0.973). Validity was proved 
by the high agreement observed between Phase I and Phase II (k=0.78–0.94; % agreement: 89.7–97.2%; p<0.001); and between Phase II and Phase 
III (k=0.8–0.9; % agreement: 90.2–94.8%; p<0.001).
Conclusion: VCAT method is a standardized causal assessment tool that gives valid and reproducible results. It has shown good agreement with the 
expert judgment method. This method may overcome the limitations enthralled with existing methods of causality assessment.
Keywords: Angiotensin-converting enzyme inhibitors, Adverse drug reaction, Causality, Method, Rater.
INTRODUCTION
Causality assessment is a pivotal tread of signal evaluation, to estimate 
the likelihood of drug in causing the adverse drug reaction (ADR) [1,2]. 
Monitoring of ADRs will aid in quantifying the risk associated with drugs. 
Non-drug causes acting as confounding factors may also be identified by 
careful assessment of the adverse event. Hence, causality assessment is 
crucial to decide the further course of the treatment in clinical trials and 
to validate signals in spontaneous reporting practice [2,3].
Numerous methods of causality assessment have been developed and 
reported over the years, which have been for broadly classified as: 
(1) Global introspection or expert judgment, (2) Bayesian approaches 
or probabilistic approaches, and (3) standardized assessment methods 
or algorithms [2,4]. Among these, global introspection is the most 
commonly used method where an expert’s judgment is used to assign 
categories based on the association between the drug and the event. 
World Health Organization-Uppsala Monitoring Centre (WHO-UMC) 
assessment method is widely practiced. However, WHO-UMC method 
suffers from limitations of intra-rater and inter-rater variability [4-6]. 
Bayesian method uses prior/background information (epidemiological 
data) and reported event information to calculate posterior probability 
which represents the probability of the drug in causing the event [7]. 
These methods can simultaneously measure probability of multiple 
factors including drugs [6,7]. The major limitations of these methods 
include complexity, non-user friendliness, and time-consumption; 
hence, not very helpful in routine practice [4,8]. Among the standardized 
tools of causal assessment, Naranjo’s algorithm is widely in practice. 
This method has a disadvantage of using the pathological data which 
might not always be reported/or available [4,9,10].
Considering the limitations encountered with the present evaluation 
methods, there is a need for a method which is comparatively 
uncomplicated and encompasses standard parameters. This method may 
consider additional queries, incorporate the effects of drug interactions, 
class effect of drugs which are not quantified by methods in practice. This 
novel method should aim to attenuate inter-rater variability in addition 
to being reproducible and valid. The versatile causality assessment tool 
(VCAT) method developed during this study has the potential to be a 
versatile method that could provide reproducible results and minimize 
the variations among raters. Hence, through this study, we aim to establish 
the reliability and validity of the newly developed method of causality 
assessment using angiotensin-converting enzyme (ACE) inhibitors.
ACE inhibitors such as ramipril, enalapril, captopril, and fosinopril are a 
widely-used class of antihypertensive drugs. These are known to cause 
several adverse events; cough being the most common, often leading 
to drug discontinuation. Other serious events include angioedema and 
pancreatitis which could be life-threatening or fatal [11].
METHODS
VCAT description and instructions for use
VCAT may be a versatile tool to assess the causal association of the 
suspected adverse event to the drug. This method included five categories 
for causal assessment (certain, probable, possible, unclassified, and 
unlikely) and incorporates information on 10 parameters, reported in a 
case for suspectedness of the event. These parameters include: Time to 
onset (TTO), dechallenge (D), evidence in literature (L), class effect (C), 
dose dependency/response (DR), lab data/biopsy results supporting 
the event (LD), rechallenge (R), drug-drug interactions (DDI), medical 
history (H), and confounding drugs (CD). These parameters are 
explained in terms of the scope of the information as follows:
TTO: TTO is the temporal association between drug administration and 
event onset. Favorable response represents a time-related association; 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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unfavorable represents inconsistent timing for the drug to cause the 
suspected ADR; and unknown value represents the unassessable 
temporal association.
D: Improvement or recovery after discontinuation or dose reduction 
of the drug explains dechallenges. Favorable dechallenge denotes a 
positive outcome after drug discontinuation; vice versa in unfavorable; 
and unknown value denotes insufficient information. If the corrective 
treatment is given and the event resolves, dechallenge is taken as 
unknown as the role of the suspect drug cannot be accurately defined.
L: Evidence of the occurrence of similar events with the same drug 
reported in literature is important due to the scientific validity of the 
literature reports. Favorable denotes well-reported ADR with the drug 
in question; unfavorable denotes reports certainly specifying that the 
event in question is improbable with the suspect drug (this information 
will not generally be reported as no certainty can be provided); and 
unknown value denotes there is limited information in literature, or the 
drug is new.
C: Class effect is an important parameter to assess the role of the similar 
chemical structures in causing similar ADRs. Favorable effect represents 
well-reported ADR of a class of drugs; unfavorable effect represents 
certainty that the event in question is dubious with the class of drugs 
(this information will not generally be reported as no certainty can be 
provided); and unknown represents lack of information or newer drug 
with no drugs of the same class.
DR: Dose-response represents the effect of dose on the occurrence or 
intensity/severity of the adverse event. Some events occur particularly 
with the overdose of a drug while few conditions can aggravate with 
the increase in dose and can have a linear or exponential relationship. 
Favorable value symbolizes the role of dose in causing or aggravating 
the event; unfavorable symbolizes certainty that dose modifications 
will not cause/aggravate the event; and unknown value symbolizes lack 
of information about dose response to the ADR.
LD: Laboratory data supporting the event strengthens the evidence of 
the event in question. Favorable value signifies data supporting the event 
in question; unfavorable value signifies data opposing the event (this 
will impact the assessment adversely); and unknown value signifies lack 
of information or ambiguous information or reported without units.
R: Recurrence of the event on restarting the drug is a pivotal parameter 
to ascertain the role of the drug. Favorable value denotes positive 
rechallenge; unfavorable value signifies negative rechallenge; and 
unknown signifies lack of information. In general, rechallenge is not 
practiced due to ethical reasons, and the positive values are generally 
the results of accidental exposures/administrations or due to 
polypharmacy or self-medication.
DDI: DDIs can affect the causal assessment as the drug’s plasma/tissue 
concentration can be modified by other drugs leading to adverse drug 
events which can otherwise not be explained by the drug in question. 
Favorable value will have a negative impact on the likelihood of 
association and reduces the margin of association; unfavorable value 
signifies non-existence of DDI (this cannot be reported with certainty 
as extensive pharmacokinetic/pharmacodynamic studies are needed to 
ascertain); and unknown value signifies limited information about the 
concurrent use of the drugs in question or blood levels of both drugs or 
reported interactions.
H: Medical history is an etiological parameter that includes risk factors, 
concurrent conditions, family history, and underlying conditions. 
Favorable value will have a negative impact on the likelihood of 
association and reduces the margin of association; unfavorable value 
denotes that the patient is otherwise healthy with no medical conditions 
and this will increase the likelihood of association; and unknown value 
denotes limited information about the medical history of the patient.
CD: Concomitant drugs taken by the patient during the course of the 
drug in question, could act as confounding factors depending on 
their individual temporal association with the event. Favorable value 
signifies that the patient is taking other drugs that can act as alternative 
explanations and this will negatively impact the likelihood; unfavorable 
value signifies that the patient is not taking any other drugs and this 
will increase the likelihood of association; and unknown value signifies 
limited information about the use of concomitant medications.
Each of the 10 parameters can have favorable, unfavorable, or unknown 
value; and depending on this value, individual scoring is done. Favorable 
depicts positive values, unfavorable depict negative values and unknown 
depicts unassessable, limited or contradictory information. Each of the 
parameters is given a score depending on the information present in the 
case as presented in Table 1. In the end, all the scores are multiplied to 
reach a final score and categorized into 1 of the 5 categories.






The final score can range from a minimum of 0.02 to a maximum of 87.9. 
The minimum score might never be obtained since rechallenge will be 
not be performed if other causes explain the occurrence of the event; 
clearly indicating that other factors provide more likely explanations 
for the adverse event. The maximum value of 87.9 is also very rare; 
depicting high level of certainty that the event is related to the drug in 
question (none of the cases in this study achieved this value). All the 
parametric information used in assessment is based on the information 
at a specific point of time, i.e., in case of change of information (receipt of 
new information), parameter can change; hence, significantly affecting 
the case categorization.
Table 1: VCAT parametric table
Parameters/Condition Favorable (Yes) Unfavorable (No) Unknown Score
TTO 6 0.1 1
D 1.5 1 1
L 1.25 1 1
C 1.25 1 1
DR 1.25 1 1
LD 1.25 0.5 1
R 4 0.75 1
DDI 0.5 1 1
H 0.75 1 1
CD 0.75 1 1
Total score (by multiplication of all individual scores): TTO x D x L x C x DR x LD x R x DDI x H x CD
TTO: Time to onset; D: Dechallenge; L: Evidence in literature; C: Class effect; DR: Dose dependency/response; LD: Lab data/biopsy results supporting the event; 
R: Rechallenge; DDI: Drug-drug interactions; H: Medical history; CD: Confounding drugs. VCAT: Versatile causality assessment tool
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In general, the score for each parameter ranges from 0.5 to 1.5. These 
values were adjusted after carefully considering extreme possible 
scenarios also keeping in mind the minimum and maximum values 
for the categories. By lowering the value, case category could change 
to a lower one, and by increasing the value, the category could be 
changed to an upper category. TTO is the foremost factor to decide 
the role of the drug; hence, more weightage has been given to it (6 for 
compatible and 0.1 for incompatible). Another important parameter, 
rechallenge has been given extra weightage in terms of score due to the 
significant impact of the parameters on the overall categorization of the 
assessment. During the preliminary analysis, this extra weightage given 
to these two parameters improved the results. Alternative etiologies 
(medical history and CD) if favorable, value is 0.75 for each parameter, 
reducing the overall score; and chances of the case of falling in a lower 
category are increased. If unfavorable, value is 1.5 for each parameter, 
increasing the overall score and chances of falling in a higher category 
are increased. For the cases with ADRs due to drug withdrawal, 
interpretation of the data is important as the withdrawal would relate 
to dechallenge and repeated withdrawal would relate to rechallenge. 
Other parameters remain the same.
Data collection
To identify all case reports related to “ADR with antihypertensive drugs,” 
a literature search from the year 1990 to February 25, 2016 (search 
date) was performed in Embase and Medline databases (through 
Embase.com). Non-human/Preclinical studies were excluded. The drug 
class (“antihypertensive agent”/exp/mj) was restricted to major focus 
to retrieve the most relevant outputs in Embase.com.
A total of 7845 citations were retrieved and manually triaged from the 
indexing and abstract. All citations which were relevant for ADRs or were 
doubtful were shortlisted/retained. Only citations published in English 
language containing information related to the keywords of interest were 
retained, all foreign languages citations were excluded. The retained 
citations (approximately 5000) were checked for the availability of their 
full-text publications. After the availability of the full-text publications, 
first 1500 most recently, published articles were selected and were 
thoroughly reviewed for the occurrence of adverse events after the use 
of antihypertensive drugs. A total of 209 of these articles were identified 
to be irrelevant to our study due to the various reasons such as adverse 
events not occurring with antihypertensive drugs; lack of efficacy was 
reported; full-text articles were in foreign language and not English; no 
adverse event was reported; multiple unidentifiable patients; review 
articles; and duplicates. The remaining 1291 articles were screened 
to identify case reports with overdose (accidental and intentional) of 
antihypertensive drugs. A total of 160 articles reported overdose of 
antihypertensive drugs; which were removed from the analysis since 
the adverse drug event profile of a drug could differ substantially at an 
overdose. The remaining 1131 articles were included in the study and 
were identified with 1339 drug-event pairs as: (1) Few articles reported 
multiple patients and (2) few articles reported multiple events with 
different drugs in the same patient at different time intervals.
The selected 1339 drug-event pairs will be denoted as “cases” 
henceforth, which were further classified into the pharmacological 
classification of antihypertensive drugs: ACE inhibitors, beta-blocker, 
calcium channel blockers, diuretics, alpha-blocker, alpha-agonist, 
angiotensin receptor blockers, phosphodiesterase-5 inhibitors, and 
miscellaneous. Miscellaneous drugs included vasodilators, alkaloids, 
centrally acting antihypertensive, endothelin receptor antagonist, renin 
inhibitor, tyrosine inhibitor, and imidazoline antagonist.
Among these 1339 cases, 427 cases were identified with suspected adverse 
events occurring to ACE inhibitors. These cases were hence used for the 
reliability and validity testing of the newly developed VCAT method.
Procedure
The selected 427 cases were assessed by multiple raters at multiple 
time points to establish the validity and reliability of the VCAT method.
WHO-UMC method rates association between drug and event in one of 
the six categories (certain, probable, possible, unlikely, unclassified, and 
unclassifiable) and however, VCAT method has five categories (certain, 
probable, possible, unclassified, and unlikely). Literature case reports 
are clinically confirmed; hence, none of the cases were identified with 
insufficient information. Therefore, unclassified and unclassifiable 
categories (of the WHO-UMC method); and unclassified category (of the 
VCAT method), were not applicable to any of the cases. Thus, in both the 
methods, only four categories were applicable.
A total of 3 raters (1 physician with over 20 years of clinical experience, 
1 pharmacologist with 15 years of experience, and 1 pharmacist with 
more than 7 years of experience in causality assessment) were involved 
in the assessment conducted in 3 phases.
Phase I: All 3 raters assessed 427 cases independently with VCAT 
method (referred to as 0-day reading) and were placed in 1 of the 
four applicable categories. Each of the 10 parameters could have 
favorable (yes), unfavorable (no) or unknown value, and depending 
on this value, scoring was done. In the end, all the scores were 
multiplied to reach a final score, and categorization was done based 
on	 the	 final	 score:	Certain	 (>20),	probable	 (>14–20),	possible	 (>2–
14), and unlikely (<1). Phase II: After 1 month, the 3 raters assessed 
the randomly reordered 427 cases with WHO-UMC method (referred 
to as 30-day reading) and were placed in 1 of the four applicable 
categories. This 1-month gap was given to allow the raters to forget 
the original judgments. Phase III: After another 2 months, the 3 
raters again assessed all the randomly renumbered 427 cases with 
VCAT method (referred to as 90-day reading) and were placed in 1 
of the four applicable categories. All the 3 raters met and discussed 
the results after each time interval to reach a consensus on the 
disagreement in the findings.
Reliability
Reliability testing was aimed to verify if different raters would reach at 
the same category of assessment for individual case reports at different 
time points. To test the reliability of the results with the VCAT method, 
assignments of the individual cases were statistically compared using 
Statistical Package for the Social Sciences (SPSS) 20.0. For intra-rater 
reliability, values of assignments with VCAT method at day 0 and day 
90 were compared. For inter-rater reliability, assignments from all the 
3-time intervals were compared (VCAT method at day 0, WHO-UMC 
method at day 30, and VCAT method at day 90). Intra-class coefficient 
(ICC) and Cronbach’s Alpha (for internal consistency) were used for 
measurement of intra-rater and inter-rater reliability at different time 
intervals. Percentage agreement and kappa(k) were used to measure 
inter-rater reliability.
Validity
Validity testing aimed to check the proximity of the results to that 
produced by an external standard. The WHO-UMC method was used 
as the external standard for comparison with the VCAT method. The 
physician was referred in case of doubts on categorization. k statistics 
was used for validity testing to measure agreement between the 
methods and raters.
Materials required
All ADRs were categorized into appropriate system organ classes (SOCs) 
as per the Medical Dictionary for Regulatory Activities (MedDRA) 
(latest version). Drugs acting as confounding factors were identified 
using Micromedex, Martindale, Meyler’s, and emc+ (UK database 
for respective drug labels/Investigator Brochures). Risk factors/
concurrent conditions/underlying disease acting as confounding 
factors were taken as per the discretion of the physician/existing 
literature. Inputs on laboratory data were taken as per the Common 
Terminology Criteria for Adverse Events. Information on class effect 
and past experience were referred from the existing literature and 
pharmacovigilance textbooks.
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Statistics
All the data are presented using descriptive analysis. Statistical analysis 
was carried out using SPSS from IBM, statistical version 20.0. Reliability 
was calculated using the Cronbach’s Alpha and ICC. k statistics was used 
for	measurement	of	agreement	between	methods	(ranging	from	−1	to	
+1). Per Landis and Koch [12], the values of k have been characterized 
as slight (0–0.20), fair (0.21–0.40), moderate (0.41–0.60), substantial 
(0.61–0.80), and almost perfect (0.81–1.00).
The sampling technique used in the study was convenient sampling. 
This utility calculated the sample size required to estimate a proportion 
(prevalence=40% for hypertension) [13] with a specified level of 
confidence and precision. Based on the formula, 
2
2
Z X P n (1-P)
E
=  the 
minimum required sample size was 369, where Z value was from 
standard normal distribution corresponding to the desired confidence 
level (Z=1.96 for 95% confidence interval), p (0.40) is expected true 
proportion, and E (0.05) is desired precision. We took a sample size 




Of these 427 cases, 203 ADRs (47.5%) were in male patients, and 223 
ADRs (52.2%) were in female patients, and the remaining 1 ADR (0.2%) 
was in unknown gender group. These 427 cases included 9 neonates 
(2.1%), 6 infant (1.4%), 11 children (2.6%), 7 adolescents (1.6%), 212 
adults (49.7%), 181 elderly (42.4%), and age group was unknown in 
1 case (0.2%). Death was reported in 16 (3.7%) of the 427 cases.
Event outcome was recovered in 243 cases (56.9%), recovering in 
136 cases (31.9%), not recovered in 7 cases (1.6%), worsened in 1 case 
(0.2%), unknown in 37 cases (8.7%), and fatal in 3 cases (0.7%).
Angioedema was the most frequently reported (150 [35.1%]) event 
with ACE inhibitors. The most commonly implicated drugs are 
presented in Table 2.
Reliability
In Phase I (VCAT at 0-day); inter-rater percentage agreement varied from 
93.7% to 94.1% with k ranging from 0.87 to 0.89 and ICC of reliability 
at 0.975. In Phase II (WHO-UMC at 30-day); inter-rater percentage 
agreement ranged from 91.8% to 96% with k varying from 0.83 to 0.92 
and ICC of reliability at 0.973. In Phase III (VCAT at 90-day); inter-rater 
percentage agreement varied from 93% to 94.4% with k ranging from 
0.85 to 0.89 and ICC of reliability at 0.973 (p<0.001). ICC of reliability 
suggests a high level of reproducibility. In Phase I and Phase III, a highest 
agreement was observed between Rater 1 and Rater 3 while in Phase II, a 
highest agreement was observed between Rater 1 and Rater 2 (Table 3).
Intra-rater reliability after comparing the results through VCAT method 
in Phase I (VCAT at 0-day) and Phase III (VCAT at 90-day) was high with 
a percentage agreement ranging from 92.3% to 96.3% with k ranging 
from 0.84 to 0.93 (Table 4). Rater 1 had shown maximum agreement 
followed by Rater 3 and Rater 2, respectively.
Validity
Agreement between Phase I (VCAT at 0-day) and Phase II (WHO-UMC at 
30-days) varied from 89.7% to 97.2% with k ranging from 0.78 to 0.94. 
Agreement between Phase II and Phase III (VCAT at 90-day) ranged 
from 90.2% to 94.8% with k varying from 0.8 to 0.9 (p<0.001). Rater 1 
had shown the maximum agreement in all the comparisons (Table 4).
DISCUSSION
Data indicates that VCAT method has shown a high reproducibility 
between different raters and at different intervals of time. It also shows 
good agreement with a WHO-UMC method which is a widely accepted 
method of causal association. ICC of reliability as a measure of inter-
rater reproducibility was observed at 0.97 in Phase I and Phase III 
where results were obtained using VCAT method.







Table 3: Inter‑rater agreement














Rater 1-Rater 2 94.1 0.883 0.023 0.001 96 0.921 0.019 0.001 93.4 0.866 0.025 0.001
Rater 2-Rater 3 93.7 0.869 0.025 0.001 91.8 0.827 0.028 0.001 93 0.856 0.026 0.001




ICC: Intraclass correlation coefficient
Table 4: Intra‑rater agreement

















Rater 1 97.2 0.945 0.016 0.001 94.8 0.898 0.021 0.001 96.3 0.926 0.018 0.001
Rater 2 91.1 0.816 0.029 0.001 92.3 0.840 0.027 0.001 92.3 0.840 0.027 0.001
Rater 3 89.7 0.782 0.031 0.001 90.2 0.795 0.030 0.001 93 0.856 0.026 0.001
SOC wise distribution of these 427 cases, per MedDRA 
20.1, is presented in Fig. 1. Maximum adverse events were 
related to  the  following SOCs:  Skin  and subcutaneous tissue 
disorders:  205  cases  (48%);  Gastrointestinal  disorders:  55  cases 
(12.9%); and Metabolism and nutrition disorders: 29 cases (6.8%).
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Reproducibility of the instrument is pivotal as it allows the results 
of different raters to be compared at different times and places. 
High agreement (k=0.84 to 0.93; % agreement: 92.3%–96.3%) was 
observed with VCAT method (Table 4) when comparisons were drawn 
between two assessments by the same method as day 0 (in Phase I) 
and day 90 (in Phase III), indicating intra-rater reliability of the VCAT 
method. High inter-rater agreement was observed in Phase I (r=0.975; 
k=0.87–0.89; % agreement: 93.7% to 94.1%) and Phase III (r=0.973, 
k=0.85–0.89; % agreement: 93%–94.4%) during comparison among 
all the raters (Table 3); indicating inter-rater reproducibility of the 
VCAT method.
Measurement of validity against a standard scale is also very 
important to establish the acceptability of the values from any new 
scale or method. We had used WHO-UMC method as a standard 
tool to establish the validity of our method. Content validity of the 
VCAT method was indicated with low scoring in cases with certain 
presence of alternative etiologies and high scoring in cases with true 
ADR. The concurrent validity of our method was established by the 
fact that very good agreement was seen between VCAT method and 
the WHO-UMC method in both the comparisons (Phase I vs. Phase 
II and Phase II vs. Phase III). All the raters in both the comparisons 
had a good agreement with Rater 1 showing the maximum agreement 
in both. This could be possibly because Rater 1 was a clinician with 
good clinical experience. Moreover, Rater 2 (pharmacologist) and 
Rater 3 (pharmacist) had shown good agreement between both the 
methods; indicating that VCAT method can be used effectively by non-
clinicians as well. This signifies extension of the utility of this method 
to all health-care professionals. In a study by Naranjo et al. [9], non-
experts have shown improvement in reliability with the use of the 
standardized tool.
High reproducibility was also observed in Phase II (Table 3), where 
WHO-UMC method was used (percentage agreement ranged from 
91.8% to 96% with k varying from 0.83 to 0.92 and ICC of reliability at 
0.973). Although the categories are well defined, yet some raters may 
differ on certain parameters leading to a difference in assessments. This 
finding is interesting in the view of a study by Naranjo et al. [9], where 
ICC of reliability improved from 0.49 (value obtained by an individual 
expert judgment without using any definite scale/method) to 0.92 
when ADR probability score method was used.
A high agreement between raters could be expected by chance, but this 
seemed doubtful as the data were analyzed in multiple ways, and the 
categorization of the cases was not narrow. Another likely explanation 
could be the selection of straightforward/simple case scenarios; this 
also is improbable as literature case reports have explicit data and is 
generally cumbersome to assess. Another hypothesis which seems 
plausible is the role of the assessment tool in giving reproducible 
results even when used by non-clinicians.
VCAT method improves the agreements, and at the same time, the 
disagreements in parameters among raters can also be identified. These 
disagreements can be important in specific scenarios to answer difficult 
questions in the case of new drugs and new symptoms. In our study, 
the majority of the disagreements among raters was due to differences 
in the alternative etiologies, i.e., identifying the confounding medical 
history and concomitant drugs taken by the patient; and dechallenge in 
context of corrective treatment given for the event. Pere et al. [14], in a 
study, had indicated that main causes of disagreement were a temporal 
association, alternative explanations, and dechallenge. Studies by 
Naranjo et al., 1981 [9], and Hutchinson et al. [15] reported that most of 
the disagreements among raters were due to the alternative explanations 
as the non-clinicians could miss out on some of the confounding factors. 
Hypertension and other comorbid disease including diabetes predispose 
patients to increased risk of ADRs due to the sub-optimal functioning 
of the organ systems. Other factors could be patient age and multiple 
drug therapy. These factors acted as confounding factors in a significant 
number of cases in the possible category in our study.
Studies have suggested that quantification of the parameters cannot be 
done in the WHO-UMC method; hence, there is no empirical rationale 
for the categorization of an ADR. However, with the algorithms/scales, 
classification of the categories is based on the empirical values that 
could quantify the probability of the ADR causes. Interestingly, high level 
of agreement between VCAT and WHO-UMC method signifies results 
comparable to that of global introspection method with the added benefit 
of giving reproducible results even when applied by non-clinicians. This 
agreement could also be attributed to some extent to the retrospective 
nature of the literature reports used in the study which is medically 
validated, and the assessor is unable to discuss the findings with the 
prescriber. Similar kind of findings was obtained in a study by Kane-Gill 
et al. [10], where the high agreement was observed in the retrospective 
phase (k=0.794) compared to prospective phase (k=0.635).
Inter-rater and intra-rater variations are the major limitations in all the 
methods of causality assessment. A method that could overcome this 
limitation and gives reproducible results is needed. Use of conventional 
definitions could give varying results as indicated by studies by Naranjo 
et al. [9], Karch et al. [16], Blanc et al. [17], and Koch-Weser et al. [18]. 
Causality assessment uses the available data in a systematic manner and 
helps to enhance the scientific evaluation. Inevitably, there could never be 
Fig. 1: SOC wise classification of ADRs
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a perfect agreement between different raters and different methods due to 
variation in subjective thinking, but it can be minimized so that a basic level 
of comparison could be drawn. The important characteristic of a method is 
the identification of the underlying cause of the event that might be drug or 
non-drug. This understanding will help to reduce the burden of the ADRs 
from the health-care system by evaluation of safety signals which will 
eventually help identify and reduce the risks to public health [19].
Clinical judgment is also essential while using the standardized tools as 
some of the questions can be unanswered by a scale that might require 
medical judgment. Training is needed before using the assessment tools, 
and care should be taken to minimize or avoid the error, to get good 
quality assessments. The VCAT method can be used for a wide variety of 
reports from both solicited (clinical trials, patient access programs, and 
patient-oriented programs, etc.) and unsolicited (spontaneous, literature, 
and patient registries, etc.) sources. In the case of multiple CD, VCAT 
should be applied to find the drug with the highest score which will have 
more probability in causing the adverse event. However, it is expected 
that our method may not solve some of the complex or extreme cases 
where a clinical experience might be required for certain adjustments.
CONCLUSION
VCAT is a standardized tool of causal assessment that gives reproducible 
results when compared with the WHO-UMC method and improves the 
quality of the assessment. We suggest using VCAT method for causality 
assessment in both prospective and retrospective studies to reach 
a valid and reproducible result. Results from the VCAT method may 
also be compared with other causality assessment methods to further 
confirm its validity. The applications of this method may also be implied 
to other pathological conditions and drug classes. Its use in clinical 
practice will pave the way for further improvements.
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